Uncategorised - European Medical Journal

Alcohol-Linked Pancreatitis Rates Soar Among Young Women

New data from Ontario reveals a concerning rise in alcohol-related gastrointestinal diseases among people aged 13 to 39, with young women showing the steepest increase.

Neonatal Antibiotics May Weaken Infant Vaccine Response

Early-life exposure to antibiotics may impair immune responses to routine infant vaccinations, according to new research.

New Global Framework Targets Superbugs in Hospitals

Next-generation sequencing (NGS) for antimicrobial resistance (AMR) could revolutionize hospital infection control, according to a newly proposed global framework from a team of international infection prevention experts.

Could Certain Gut Bacteria Stunt Growth?

The findings revealed that certain gut bacteria increase short stature risk.

Excess Visceral Fat Drives Cardiovascular Risk in HIV

In people with HIV taking antiretroviral therapy, excessive visceral abdominal fat drives cardiovascular disease risk, even in individuals…

Latest highlight in Prostate Cancer – from PROSCA latest edition

These four video interviews were recorded at PROSCA 2024 in Madrid, Spain. The videos explore oral androgen deprivation therapy (ADT)…

EBMT 2025 Interview: Luigi Naldini and Franco Locatelli

EBMT Interview: Luigi Naldini and Franco Locatelli. In this insightful interview, leading experts in gene therapy, Franco Locatelli and…

Optimizing Metastatic Risk Prediction in cSCC

A new study shows how gene expression profiling improves risk prediction for high-risk cutaneous squamous cell carcinoma, helping…

IFT Study Shares Fast-Acting Therapy for Acute Trigeminal Neuralgia: AAN 2025

Intravenous fosphenytoin (fPHT) demonstrated rapid and significant pain relief for patients experiencing acute exacerbations of trigeminal neuralgia (TN), according to late-breaking results from the IFT Study presented at the 2025 American Academy of Neurology (AAN) Annual Meeting in San Diego.

Ide-Cel Shows 73% Response in Complex Multiple Myeloma Cases

In the treatment of relapsed/refractory multiple myeloma, CAR T-cell therapy using idecabtagene vicleucel (ide-cel) has demonstrated encouraging results in a large real-world U.S. patient cohort, according to new data from the CIBMTR registry.